GeneBioTech Co Ltd

GeneBioTech maintains a conservative capital structure with a debt-to-equity ratio of 0.28, significantly below the median for the biotechnology industry, indicating a low reliance on debt financing. The company holds KRW 8,960.55 billion in cash and equivalents, but after subtracting long-term debt of KRW 13,831.16 billion, the net cash position is negative, signaling potential liquidity constraints. The current ratio of 3.09 suggests strong short-term liquidity, with current assets comfortably covering current liabilities.

Profitability metrics show a return on equity (ROE) of 1.42% and a return on assets (ROA) of 1.01%, both below the industry median for biotechnology firms, indicating subpar capital efficiency and asset utilization. Operating income of KRW 1,070.65 billion and net income of KRW 699.84 billion reflect a gross margin of 16.9%, which is in line with the industry but does not suggest a competitive advantage in cost control.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification, making it vulnerable to regional economic or regulatory shifts. No material revenue is attributed to international markets, and the company does not report segment-specific performance metrics.

Looking ahead, revenue is projected to grow by 12.3% in the current fiscal year and 8.1% in the next, based on the outlook derived from historical revenue trends and industry benchmarks. However, the company's capital expenditure of KRW 224.84 billion in the latest period suggests ongoing investment in infrastructure or R&D, which could impact near-term free cash flow.

Risk factors include a medium liquidity risk due to the negative net cash position and a low dilution risk, as shares outstanding have not changed between basic and diluted counts. No recent equity issuance or ATM programs have been disclosed, and the company has not flagged dilution as a material risk in its filings.

Recent events include the filing of a 2023 annual report, which disclosed continued investment in R&D and a focus on expanding its diagnostic product portfolio. No material legal or regulatory actions were reported in the latest filings.

Revenue grew 9.4% year-over-year to 90.8 billion KRW, demonstrating consistent top-line expansion over the four-year period.

Net income surged 32.2% to 3.8 billion KRW, significantly outpacing revenue growth and indicating improved operational efficiency.

The company maintains a low debt-to-equity ratio of 0.28, providing a conservative capital structure relative to peers.

Gross profit remains robust at 14.4 billion KRW, supporting a healthy gross margin despite recent net income volatility.

Dilution risk is assessed as low, suggesting current capital structure stability without immediate threats to shareholder equity.

Credit risk is flagged as high, indicating significant potential for financial distress or default given current leverage levels.

Liquidity risk is rated medium, raising concerns about the company's ability to meet short-term financial obligations.